Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

doi:10.1038/leu.2017.22

. 2017 May;31(5):1217-1220.

doi: 10.1038/leu.2017.22. Epub 2017 Jan 18.

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

R F Schlenk^{1

2}, P Frech¹, D Weber¹, P Brossart³, H-A Horst⁴, D Kraemer⁵, G Held⁶, M Ringhoffer⁷, A Burchardt⁸, G Kobbe⁹, K Götze¹⁰, D Nachbaur¹¹, T Fischer¹², M Lübbert¹³, H R Salih¹⁴, H Salwender¹⁵, G Wulf¹⁶, E Koller¹⁷, M Wattad¹⁸, W Fiedler¹⁹, S Kremers²⁰, H Kirchen²¹, B Hertenstein²², P Paschka¹, V I Gaidzik¹, V Teleanu¹, M Heuser²³, F Thol²³, K Döhner¹, J Krauter²³, A Ganser²³, H Döhner¹; the German-Austrian AMLSG

Affiliations

¹ Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
² NCT Trial Center, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
³ Department of Internal Medicine III, University Hospital of Bonn, Bonn, Germany.
⁴ Department of Internal Medicine II, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany.
⁵ Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany.
⁶ Department of Internal Medicine I, University Hospital of Saarland, Homburg, Germany.
⁷ Department of Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
⁸ Department of Hematology/Oncology, University-hospital Giessen, Giessen, Germany.
⁹ Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
¹⁰ Department of Internal Medicine III, Technical University of Munich, Munich, Germany.
¹¹ Department of Internal Medicine V, University Hospital Innsbruck, Innsbruck, Austria.
¹² Department of Medicine III, Johannes Gutenberg-University Mainz, Mainz, Germany.
¹³ Department of Hematology and Oncology, University Hospital of Freiburg, Freiburg, Germany.
¹⁴ Department of Hematology and Oncology, Eberhard-Karls University, Tübingen, Germany.
¹⁵ Department of Hematology/Oncology, Asklepios Klinik Altona, Hamburg, Germany.
¹⁶ Department of Hematology and Oncology, University Hospital of Göttingen, Göttingen, Germany.
¹⁷ Department of Hematology/Oncology, Hanuschkrankenhaus, Wien, Austria.
¹⁸ Department of Hematology Oncology, Kliniken Essen-Süd, Essen, Germany.
¹⁹ Department of Internal Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
²⁰ Department of Hematology/Oncology, Caritas-Krankenhaus, Lebach, Germany.
²¹ Department of Hematology/Oncology, Krankenhaus der Barmherzigen Brüder, Trier, Germany.
²² Department of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany.
²³ Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

PMID: 28096533
PMCID: PMC5420792
DOI: 10.1038/leu.2017.22

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

R F Schlenk et al. Leukemia. 2017 May.

. 2017 May;31(5):1217-1220.

doi: 10.1038/leu.2017.22. Epub 2017 Jan 18.

Authors

Affiliations

¹ Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
² NCT Trial Center, National Center for Tumor Diseases (NCT), Heidelberg, Germany.
³ Department of Internal Medicine III, University Hospital of Bonn, Bonn, Germany.
⁴ Department of Internal Medicine II, University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany.
⁵ Department of Oncology and Hematology, Klinikum Oldenburg, Oldenburg, Germany.
⁶ Department of Internal Medicine I, University Hospital of Saarland, Homburg, Germany.
⁷ Department of Internal Medicine III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
⁸ Department of Hematology/Oncology, University-hospital Giessen, Giessen, Germany.
⁹ Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
¹⁰ Department of Internal Medicine III, Technical University of Munich, Munich, Germany.
¹¹ Department of Internal Medicine V, University Hospital Innsbruck, Innsbruck, Austria.
¹² Department of Medicine III, Johannes Gutenberg-University Mainz, Mainz, Germany.
¹³ Department of Hematology and Oncology, University Hospital of Freiburg, Freiburg, Germany.
¹⁴ Department of Hematology and Oncology, Eberhard-Karls University, Tübingen, Germany.
¹⁵ Department of Hematology/Oncology, Asklepios Klinik Altona, Hamburg, Germany.
¹⁶ Department of Hematology and Oncology, University Hospital of Göttingen, Göttingen, Germany.
¹⁷ Department of Hematology/Oncology, Hanuschkrankenhaus, Wien, Austria.
¹⁸ Department of Hematology Oncology, Kliniken Essen-Süd, Essen, Germany.
¹⁹ Department of Internal Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
²⁰ Department of Hematology/Oncology, Caritas-Krankenhaus, Lebach, Germany.
²¹ Department of Hematology/Oncology, Krankenhaus der Barmherzigen Brüder, Trier, Germany.
²² Department of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany.
²³ Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.

PMID: 28096533
PMCID: PMC5420792
DOI: 10.1038/leu.2017.22

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
Kaplan−Meier plot illustrating the influence of the CR/CRi probability score on survival after relapse in patients receiving intensive salvage chemotherapy (a) or direct allogeneic HCT (b) as treatment of relapse. The score was based on the sum of favorable (+1) and unfavorable (−1) parameters defining three groups: low CR/CRi probability value<0; intermediate CR/CRi probability value=0, high CR/CRi probability value>0.

See this image and copyright information in PMC

Cited by

Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience.
Silva WFD, Rosa LID, Seguro FS, Silveira DRA, Bendit I, Buccheri V, Velloso EDRP, Rocha V, Rego EM. Silva WFD, et al. Clinics (Sao Paulo). 2020 Apr 6;75:e1566. doi: 10.6061/clinics/2020/e1566. eCollection 2020. Clinics (Sao Paulo). 2020. PMID: 32294670 Free PMC article.
Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.
Yuan F, Li D, Li G, Cheng C, Wei X. Yuan F, et al. Ann Transl Med. 2022 Apr;10(8):490. doi: 10.21037/atm-22-1459. Ann Transl Med. 2022. PMID: 35571387 Free PMC article.
Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia.
Böhme M, Kayser S. Böhme M, et al. Cancers (Basel). 2021 Dec 27;14(1):105. doi: 10.3390/cancers14010105. Cancers (Basel). 2021. PMID: 35008269 Free PMC article. Review.
Targeting FLT3 mutations in AML: review of current knowledge and evidence.
Daver N, Schlenk RF, Russell NH, Levis MJ. Daver N, et al. Leukemia. 2019 Feb;33(2):299-312. doi: 10.1038/s41375-018-0357-9. Epub 2019 Jan 16. Leukemia. 2019. PMID: 30651634 Free PMC article. Review.
Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study.
Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ. Kayser S, et al. Haematologica. 2020 Jan;105(1):161-169. doi: 10.3324/haematol.2018.208678. Epub 2019 Apr 19. Haematologica. 2020. PMID: 31004014 Free PMC article.

See all "Cited by" articles

References

1. Schlenk RF, Döhner H. Genomic applications in the clinic: use in treatment paradigm of AML. Am Soc Hematol Educ Program 2013; 2013: 324–330. - PubMed
1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015; 373: 1136–1152. - PubMed
1. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474. - PubMed
1. Ravandi F. Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Haematol 2013; 26: 253–259. - PMC - PubMed
1. Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 1969–1978. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Schlenk RF, Döhner H. Genomic applications in the clinic: use in treatment paradigm of AML. Am Soc Hematol Educ Program 2013; 2013: 324–330. - PubMed

[2] Schlenk RF, Döhner H. Genomic applications in the clinic: use in treatment paradigm of AML. Am Soc Hematol Educ Program 2013; 2013: 324–330. - PubMed

[3] Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015; 373: 1136–1152. - PubMed

[4] Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med 2015; 373: 1136–1152. - PubMed

[5] Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474. - PubMed

[6] Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474. - PubMed

[7] Ravandi F. Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Haematol 2013; 26: 253–259. - PMC - PubMed

[8] Ravandi F. Relapsed acute myeloid leukemia: why is there no standard of care? Best Pract Res Clin Haematol 2013; 26: 253–259. - PMC - PubMed

[9] Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 1969–1978. - PubMed

[10] Breems DA, Van Putten WL, Huijgens PC, Ossenkoppele GJ, Verhoef GE, Verdonck LF et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005; 23: 1969–1978. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

Affiliations

Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia

Authors

Affiliations

Conflict of interest statement

Figures

Similar articles

Cited by

References

MeSH terms

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical